{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:05Z","timestamp":1792701845457,"version":"4.5.0"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hyperprolactinemia is a commonly underestimated adverse effect of\nantipsychotic medications. There are still no consensus guidelines for the optimal monitoring\nand treatment strategies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of the study was to assess the monitoring and treatment practices of antipsychotic-\ninduced hyperprolactinemia, in addition to the prevalence and risk factors associated with\nit.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A retrospective cohort observational study was conducted among patients attending\nthe psychiatric clinics at an academic tertiary hospital in Riyadh, Saudi Arabia, from May 2020\nuntil May 2021, by reviewing each patient\u2019s medical record for up to five years.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Among the 662 patients, 35 patients (5.3%) and 242 patients (36.6%) had their serum\nprolactin levels monitored (at baseline and at follow-up, respectively). The prevalence of hyperprolactinemia\nwas observed in 212 patients (32%). Only 76 patients (36%) were symptomatic.\nFemale gender, younger age, and bipolar disorder had a significantly higher risk of developing\nhyperprolactinemia. 60% of the confirmed cases received treatment, of which 76 (60%) were\nadherent to treatment guidelines. The most common treatment strategies implemented were dose\nreduction (42.5%) and aripiprazole augmentation (29.1%).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It is imperative to conduct a baseline check of prolactin levels before commencing\nany antipsychotic therapy. Similarly, routine prolactin level monitoring is recommended regardless\nof symptoms in patients treated with antipsychotics with a possible prolactin-raising effect.\nAdherence to evidence-based treatment guidelines can improve patient quality of life and therapeutic\ncompliance.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748863280407240305070905","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:34:30Z","timestamp":1710473670000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Monitoring and Management Practices of Antipsychotic-Induced Hyperprolactinemia at a Medical City in Riyadh, Saudi Arabia: A Retrospective Cohort Study"],"prefix":"10.2174","volume":"20","author":[{"given":"Zahra","family":"Hussain Alshabeeb","sequence":"first","affiliation":[{"name":"Psychiatric Clinical Pharmacy Services; Erada Complex for Mental Health, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashayr","family":"Alsuwayni","sequence":"additional","affiliation":[{"name":"Ambulatory Care Clinical Pharmacy Services, King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alshargi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Riyadh Elm\nUniversity, Riyadh 11681, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Abdelazeem","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Riyadh Elm\nUniversity, Riyadh 11681, Saudi Arabia"},{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef\nUniversity, Beni-Suef 62514, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","volume":"28","author":"Peuskens J.","year":"2014","unstructured":"Peuskens J.; Pani L.; Detraux J.; De Hert M.; The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs  2014,28(5),421-453","journal-title":"CNS Drugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","volume":"22","author":"Alosaimi F.D.","year":"2018","unstructured":"Alosaimi F.D.; Fallata E.O.; Abalhassan M.; Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract  2018,22(4),274-281","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"Byerly M.","year":"2007","unstructured":"Byerly M.; Suppes T.; Tran Q.V.; Baker R.A.; Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol  2007,27(6),639-661","journal-title":"J Clin Psychopharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1192\/apt.bp.115.014928","volume":"23","author":"Gupta S.","year":"2017","unstructured":"Gupta S.; Lakshmanan D.A.M.; Khastgir U.; Nair R.; Management of antipsychotic-induced hyperprolactinaemia. BJ Psych Adv  2017,23(4),278-286","journal-title":"BJ Psych Adv"},{"key":"ref=5","first-page":"929","volume":"3","author":"Torre D.L.","year":"2007","unstructured":"Torre D.L.; Falorni A.; Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag  2007,3(5),929-951","journal-title":"Ther Clin Risk Manag"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"Melmed S.","year":"2011","unstructured":"Melmed S.; Casanueva F.F.; Hoffman A.R.; Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab  2011,96(2),273-288","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","volume":"45","author":"Montejo \u00c1.L.","year":"2017","unstructured":"Montejo \u00c1.L.; Arango C.; Bernardo M.; Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol  2017,45,25-34","journal-title":"Front Neuroendocrinol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","volume":"6","author":"Tewksbury A.","year":"2016","unstructured":"Tewksbury A.; Olander A.; Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin  2016,6(4),185-190","journal-title":"Ment Health Clin"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","volume":"29","author":"Bostwick J.R.","year":"2009","unstructured":"Bostwick J.R.; Guthrie S.K.; Ellingrod V.L.; Antipsychotic\u2010induced hyperprolactinemia. Pharmacotherapy  2009,29(1),64-73","journal-title":"Pharmacotherapy"},{"key":"ref=10","unstructured":"Psychosis and schizophrenia in adults: Prevention and management. NICE  https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","volume":"74","author":"Holt R.I.G.","year":"2011","unstructured":"Holt R.I.G.; Peveler R.C.; Antipsychotics and hyperprolactinaemia: Mechanisms, consequences and management. Clin Endocrinol  2011,74(2),141-147","journal-title":"Clin Endocrinol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/0269881107087346","volume":"22","author":"Peveler R.C.","year":"2008","unstructured":"Peveler R.C.; Branford D.; Citrome L.; Antipsychotics and hyperprolactinaemia: Clinical recommendations. J Psychopharmacol  2008,22(S2),98-103","journal-title":"J Psychopharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0269881107086516","volume":"22","author":"Walters J.","year":"2008","unstructured":"Walters J.; Jones I.; Clinical questions and uncertainty \u2014 Prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol  2008,22(S2),82-89","journal-title":"J Psychopharmacol"},{"key":"ref=14","first-page":"575","volume":"169","author":"Serri O.","year":"2003","unstructured":"Serri O.; Chik C.L.; Ur E.; Ezzat S.; Diagnosis and management of hyperprolactinemia. Can Med Assoc J  2003,169(6),575-581","journal-title":"Can Med Assoc J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/0004-2730000003002","volume":"58","author":"Vilar L.","year":"2014","unstructured":"Vilar L.; Fleseriu M.; Bronstein M.D.; Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol  2014,58(1),9-22","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28","author":"Kinon B.J.","year":"2003","unstructured":"Kinon B.J.; Gilmore J.A.; Liu H.; Halbreich U.M.; Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone11This work was sponsored by Eli Lilly and Company. Psychoneuroendocrinology  2003,28(S2),55-68","journal-title":"Psychoneuroendocrinology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0228648","DOI":"10.1371\/journal.pone.0228648","volume":"15","author":"Dehelean L.","year":"2020","unstructured":"Dehelean L.; Romosan A.M.; Papava I.; Prolactin response to antipsychotics: An inpatient study. PLoS One  2020,15(2),e0228648","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e7005","DOI":"10.7759\/cureus.7005","volume":"12","author":"Alhussain H.","year":"2020","unstructured":"Alhussain H.; Aldayel A.A.; Alenazi A.; Alowain F.; Multiple sclerosis patients in Saudi Arabia: Prevalence of depression and its extent of severity. Cureus  2020,12(2),e7005","journal-title":"Cureus"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1111\/j.1743-6109.2010.01709.x","volume":"7","author":"Montejo \u00c1.L.","year":"2010","unstructured":"Montejo \u00c1.L.; Majadas S.; Villademoros R.F.; Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med  2010,7(10),3404-3413","journal-title":"J Sex Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","volume":"45","author":"Correll C.U.","year":"2006","unstructured":"Correll C.U.; Carlson H.; Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry  2006,45(7),771-791","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/endo-108-2-440","volume":"108","author":"Gudelsky G.A.","year":"1981","unstructured":"Gudelsky G.A.; Nansel D.D.; Porter J.C.; Role of estrogen in the dopaminergic control of prolactin secretion. Endocrinology  1981,108(2),440-444","journal-title":"Endocrinology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/00048674.2011.589044","volume":"45","author":"Inder W.J.","year":"2011","unstructured":"Inder W.J.; Castle D.; Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry  2011,45(10),830-837","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.3390\/ijerph17155594","volume":"17","author":"Rodr\u00edguez G.A.","year":"2020","unstructured":"Rodr\u00edguez G.A.; Gu\u00e0rdia A.; Pedrero A.A.; Women with schizophrenia over the life Span: Health promotion, treatment and outcomes. Int J Environ Res Public Health  2020,17(15),5594","journal-title":"Int J Environ Res Public Health"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajhp\/zxab065","volume":"78","author":"Rusgis M.M.","year":"2021","unstructured":"Rusgis M.M.; Alabbasi A.Y.; Nelson L.A.; Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm  2021,78(10),862-871","journal-title":"Am J Health Syst Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.17816\/phf46072","volume":"2","author":"Dorovskikh V.","year":"2020","unstructured":"Dorovskikh V.; Pavlova A.; Scheidegger M.; Cariprazine is a modern antipsychotic with a favorable neuroendocrine profile. Biomed Sci  2020,2(3),58-63","journal-title":"Biomed Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bdi.12701","volume":"20","author":"Mulder R.","year":"2018","unstructured":"Mulder R.; Hamilton A.; Irwin L.; Boyce P.; Morris G.; Porter R.; Treating depression with adjunctive antipsychotics. Bipolar Disord  2018,20(S2),17-24","journal-title":"Bipolar Disord"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00787-020-01705-2","volume":"31","author":"Lertxundi N.","year":"2021","unstructured":"Lertxundi N.; Molinueve A.; Valvi D.; Gorostiaga A.; Balluerka N.; Shirappa N.; Dietary inflammatory index of mothers during preganacy and attention deficit-hyperactivity disorder systems in the child at preschool age: A prospective investigation in the INMA and RHEA cohorts. Eur Child Adolesc Psychiatry  2021,31(4),615-624","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-020-0507-8","volume":"20","author":"Budayr A.","year":"2020","unstructured":"Budayr A.; Tan T.C.; Lo J.C.; Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: The CATCH study. BMC Endocr Disord  2020,20(1),25","journal-title":"BMC Endocr Disord"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"Chen C.K.","year":"2010","unstructured":"Chen C.K.; Huang Y.S.; Ree S.C.; Hsiao C.C.; Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry  2010,34(8),1495-1499","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.681418","volume":"12","author":"Zhuo C.","year":"2021","unstructured":"Zhuo C.; Xu Y.; Wang H.; Fang T.; Chen J.; Zhou C.; Safety and efficacy of high-dose vitamin B6 as an adjunctive treatment for antipsychotic-induced hyperprolactinemia in male patients with treatment-resistant schizophrenia. Sec Psychopharmacol  2021,12,1-11","journal-title":"Sec Psychopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/167138","volume":"2013","author":"Wu H.","year":"2013","unstructured":"Wu H.; Deng L.; Zhao L.; Zhao J.; Li L.; Chen J.; Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol  2013,2013,1-7","journal-title":"Int J Endocrinol"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863280407240305070905","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227900\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863280407240305070905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:45:29Z","timestamp":1747741529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227900\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748863280407240305070905","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}